| abstract |
The present disclosure provides a liquid formulation suitable for a group B adenovirus, comprising: a) a group B adenovirus, such as replication competent group B adenovirus, b) 15 to 25 pcnt v/v glycerol, for example 16, 17, 18, 19, 20, 21 pcnt v/v glycerol; and c) 0.1 to 1.5 pcnt v/v ethanol, for example 0.2-1 pcnt , such as 1 pcnt v/v ethanol; and d) a buffer, and e) optionally an amino acid, wherein the pH of the formulation is in the range 8.0 to 9.6, and use of the same in treatment, particular in the treatment of cancer. |